Chargement de la fiche…
rhumatologie
Pr Bernard Combe
Professeur des universités
Rheumatoid Arthritis Research and Therapies · Spondyloarthritis Studies and Treatments · Systemic Lupus Erythematosus Research
0Publications
0Citations
0Thèses dirigées
0Vidéos
0Citations de la publi la +
Enseignement
Côté patient
Avant votre rendez-vous avec le Pr Bernard Combe
Choisissez votre pathologie pour une explication en langage simple.
Parcourir toutes les pathologies →Des applications évaluées par MonRhumato, sélectionnées pour les patients.
MapathoPlateforme communautaire maladies chroniques + annuaire pair-validé
GustaveAgent IA souverain pour information patient sourcée
Remedee LabsBracelet stimulateur d'endorphines pour douleur chroniquePourquoi consulter Pr Bernard Combe
- Auteur de référence en rhumatologie
- Encadrant universitaire
- Conseils vidéo gratuits
- Référence presse grand public
Tout est calculé à partir des sources publiques (RPPS, PubMed, OpenAlex, OpenStreetMap…) — aucun classement éditorial.
Parcours
2021
Roche (Switzerland)
2016
Université Claude Bernard Lyon 1
2016
Goethe University Frankfurt
2014–2015
Leiden University
2015
Hospital for Special Surgery
2013–2014
Université de Tours
Rayonnement scientifique
0
h-index
0
i10
0
citations
Le h-index mesure la productivité scientifique : ce médecin a publié 86 articles cités au moins 86fois par d'autres chercheurs. Plus c'est élevé, plus son travail influence la communauté médicale.
Dernières publications
Publications les plus citées
127 citationsEULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update2022 · Annals of the rheumatic diseasesPubMed ↗92 citationsA Risk Score to Detect Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease2022 · Arthritis & rheumatology (Hoboken, N.J.)PubMed ↗53 citationsConsensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update2023 · Annals of the rheumatic diseasesPubMed ↗
Diplômes & qualifications
DES
Rhumatologie (SM) — Diplôme d'Études Spécialisées
CES
CES Rhumatologie · DE Docteur en médecine · Diplôme relatif à la Réparation juridique du dommage corporel · Cancérologie (C) — Capacité / Certificat d'Études Spéciales
DU / DIU
DU Réparation juridique du dommage corporel
Formation à l'expertise médicale dans les procédures juridiques (accidents du travail, AT/MP, indemnisation). Le rhumato expertise les conséquences fonctionnelles.
Plusieurs universités françaises
Lieu d'exercice
localisation non renseignée
Domaines d'expertise
Rheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and TreatmentsSystemic Lupus Erythematosus ResearchAutoimmune and Inflammatory Disorders ResearchChronic Lymphocytic Leukemia Research
Bibliométrie (OpenAlex)
Profil ↗0
travaux
0
h-index
0
i10-index
0
citations
Rheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and TreatmentsSystemic Lupus Erythematosus ResearchAutoimmune and Inflammatory Disorders ResearchChronic Lymphocytic Leukemia Research
Transversal
212026Arthritis & rheumatology (Hoboken, N.J.)
PubMed ↗EULAR/American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia
2026Rheumatology (Oxford, England)
PubMed ↗Reliability of ultrasound assessment of elementary lesions in psoriatic arthritis and development of a reference dactylitis atlas
2026Respirology (Carlton, Vic.)
PubMed ↗Effects of Air Pollution Exposure and the MUC5B rs35705950 Variant on Interstitial Lung Disease Risk in Patients With Rheumatoid Arthritis
2026Rheumatology (Oxford, England)
PubMed ↗Stability and prognostic value of B-cell markers in primary SS: results from the French ASSESS cohort
2025Joint bone spine
PubMed ↗Early peripheral psoriatic arthritis: Baseline features of the first 186 patients in the French Nationwide APACHE Cohort
2025Annals of the rheumatic diseases
PubMed ↗EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia
2024RMD open
PubMed ↗Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort
2024Joint bone spine
PubMed ↗Ten-year clinical outcome of recent-onset axial spondyloarthritis: Results from the DESIR inception Cohort
2024Journal of clinical medicine
PubMed ↗Repurposing the Fibrosis-4 Score in Rheumatoid Arthritis: Data from the ESPOIR Cohort
2023RMD open
PubMed ↗Distinction and prognosis of early arthritis phenotypes: an analysis in three European cohorts
2023Arthritis care & research
PubMed ↗Identification of Symptom Phenotypes of Hand Osteoarthritis Using Hierarchical Clustering: Results From the DIGICOD Cohort
2023Arthritis care & research
PubMed ↗Influence of Social Support, Financial Status, and Lifestyle on the Disparity Between Inflammation and Disability in Rheumatoid Arthritis
2023Clinical and experimental rheumatology
PubMed ↗Clinical significance of a self-reported familial occurrence of rheumatoid arthritis among patients with recent-onset arthritis: data from the ESPOIR cohort
2022Rheumatology (Oxford, England)
PubMed ↗Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis
2022Annals of the rheumatic diseases
PubMed ↗EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update
2022Arthritis & rheumatology (Hoboken, N.J.)
PubMed ↗A Risk Score to Detect Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease
2022Joint bone spine
PubMed ↗Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma
2022European journal of immunology
PubMed ↗Glutamine promotes the generation of B10(+) cells via the mTOR/GSK3 pathway
2022Joint bone spine
PubMed ↗Impact of multimorbidity on disease modifying antirheumatic drug therapy in early rheumatoid arthritis: Data from the ESPOIR cohort
2022Annals of the rheumatic diseases
PubMed ↗Fat mass and response to TNFα blockers in early axial spondyloarthritis: an analysis of the DESIR cohort
2022Rheumatology (Oxford, England)
PubMed ↗CXCR5/CXCL13 pathway, a key driver for migration of regulatory B10 cells, is defective in patients with rheumatoid arthritis
JAK inhibiteurs
122025Modern rheumatology
PubMed ↗Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4
2024RMD open
PubMed ↗Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study
2024RMD open
PubMed ↗Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study
2023Rheumatology and therapy
PubMed ↗Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
2023Rheumatology and therapy
PubMed ↗Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
2023Modern rheumatology
PubMed ↗Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results
2023Rheumatology and therapy
PubMed ↗Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
2023Rheumatology and therapy
PubMed ↗Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
2022Arthritis & rheumatology (Hoboken, N.J.)
PubMed ↗Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension
2022RMD open
PubMed ↗Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
2022Modern rheumatology
PubMed ↗Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1)
2022Arthritis research & therapy
PubMed ↗The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies
csDMARDs
62023Rheumatology and therapy
PubMed ↗Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
2023Modern rheumatology
PubMed ↗Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results
2023RMD open
PubMed ↗Should we stop methotrexate or not for vaccination?
2023Rheumatology and therapy
PubMed ↗Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
2022Arthritis research & therapy
PubMed ↗Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination
2022Modern rheumatology
PubMed ↗Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1)
Anti-IL-17
32022Clinical rheumatology
PubMed ↗Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
2022Clinical rheumatology
PubMed ↗Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
2022Annals of the rheumatic diseases
PubMed ↗Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
Biothérapies non-anti-TNF
32025Frontiers in medicine
PubMed ↗Long-term management of elderly patients with rheumatoid arthritis treated with tocilizumab: comparison of patients over and under 75 years old
2024RMD open
PubMed ↗Risk of severe infection associated with immunoglobulin deficiency under rituximab therapy in immune-mediated inflammatory disease
2022Rheumatology (Oxford, England)
PubMed ↗Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept
Stratégie thérapeutique
32024Clinical rheumatology
PubMed ↗Adding ultrasound to treat-to-target shows no benefit in achieving clinical remission nor in slowing radiographic progression in rheumatoid arthritis: results from a multicenter prospective cohort
2023Rheumatology (Oxford, England)
PubMed ↗Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM
2022RMD open
PubMed ↗Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort
Épidémiologie & registres
22025ACR open rheumatology
PubMed ↗Polypharmacy in Early Rheumatoid Arthritis: Impact on Treatment Response and Adverse Event Risk in a multicenter French prospective cohort study
2024Rheumatology (Oxford, England)
PubMed ↗Prevalence of anti-neutrophil cytoplasmic antibody-associated vasculitis in the south of France, using the capture-recapture method
Pharmacovigilance
22025Rheumatology and therapy
PubMed ↗The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations
2025ACR open rheumatology
PubMed ↗Polypharmacy in Early Rheumatoid Arthritis: Impact on Treatment Response and Adverse Event Risk in a multicenter French prospective cohort study
Revue générale
22025Rheumatology and therapy
PubMed ↗The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations
2023Arthritis care & research
PubMed ↗Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis
Anti-TNF
12022Arthritis research & therapy
PubMed ↗Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination
Échographie
12024RMD open
PubMed ↗Persistence of power Doppler ultrasonography-detected synovitis over 1 year of follow-up predicts poor prognosis in rheumatoid arthritis in clinical remission: the SONORE prospective longitudinal study
Recommandations
12023Annals of the rheumatic diseases
PubMed ↗Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
Revue / méta-analyse
12023Arthritis care & research
PubMed ↗Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis
Santé mentale / fatigue
12022Clinical and experimental rheumatology
PubMed ↗Trajectories in early rheumatoid arthritis related fatigue over 10 years: results from the ESPOIR cohort
Publications HAL
82026Article
Stability and prognostic value of B-cell markers in primary Sjögren’s syndrome: results from the French ASSESS cohort
Rheumatology
2026Article
Reliability of ultrasound assessment of elementary lesions in psoriatic arthritis and development of a reference dactylitis Atlas
Rheumatology
2025Article
Early peripheral psoriatic arthritis: Baseline features of the first 186 patients in the French Nationwide APACHE Cohort
Joint Bone Spine
2025Article
EULAR /American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia
Arthritis & rheumatology
2025Article
Polypharmacy in Early Rheumatoid Arthritis: Impact on Treatment Response and Adverse Event Risk in a multicenter French prospective cohort study
ACR Open Rheumatology
2024Article
Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort
Rheumatology
2024Article
Persistence of power Doppler ultrasonography-detected synovitis over 1 year of follow-up predicts poor prognosis in rheumatoid arthritis in clinical remission: the SONORE prospective longitudinal study
RMD Open
2024Congrès
Interaction of High Air Pollution Exposure and MUC5B rs35705950 on Interstitial Lung Disease Risk in Rheumatoid Arthritis Patients
2024 ERS Congress
Vidéos
6
▶Le Filgotinib, nouveau médicament en cours de développement
Polyarthrite Andar
▶Author Interview - Professor Combe
The Immune-Mediated Inflammatory Disease Forum
▶#03 « Les Traitements Anti-JAK » par le Pr Bernard COMBE
Polyarthrite Andar
▶Interview Pr Bernard Combe eular 2017
Polyarthrite Andar
▶HAS - Quels sont les objectifs de la Société française de rhumatologie ?
HAS - Haute Autorité de santé
▶HAS - Quelles sont les actualités de la Société française de rhumatologie ?
HAS - Haute Autorité de santé
Presse
4Les Echos
La rhumatologie fait sa révolution thérapeutique - Les Echos
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNc250UXltUjNqRzltako2a3kwVTZRMEVWM01XREd4Ukk3UmsydkdDYlZFVlN3ODE5UVdLSTA5bjdCek91OElXT3l0c2FPU1NRNHFQNmpZb1BDMGZTUEVpUnR2THNiejdoQUkyWW41M0diZ3VpdnUyazduLWxmb3h3S0pmbHRIN3pESE9saXFybHM?oc=5" target="_blank">La rhumatologie fait sa révoluti
Caducée.net
Erelzi ® (étanercept) biosimilaire développé en Europe par Sandoz sera bientôt disponible en France - Caducée.net
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxPOFpteXRfSTUwc2hfRXRPMzZ3VlVaQVF5UnlENGxWUkVWV0kteEhnTk9xUlRrMm43aWt4NnZ5Mmh4Tmd1bXBfWU82VkkyMEdrMmFLOWRLZElrRnlZVVhYNC14dk5YckhNa2VvNWo0ZFE0dDV2aTEtYWVIaTAyb25JbGR0dkUwaUs0QlB0MWptdUwzOTBqOEVrdWpYVUF3ZVB1ai1SQVljLXNhOFg2S29xdURCX0Y0Yjd3bn
Le Figaro Santé
Polyarthrite rhumatoïde : à repérer dès les premiers signes - Le Figaro Santé
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOa3QtVGcwbjFaT1p3cG5ZZ19ya3pjSDlmaGtvbm1wb1dvMG1vRm9MT1NyUWNsZjJhT2t5T2oxeTFvNGFERGxIWDAwc2NnenZsekxkbDE5ZEMwX0NjUEdORmRSbnF4YXpVdlZjZ244b1FRbFRnOHpPalJwS0NEMG5iajI2ODhjTmk3M3d0Y3ZjUnFWaDVKNXlMcXhyTS02emRZOUE?oc=5" target="_blank">Polyarth
Revue Médicale Suisse
Polyarthrite rhumatoïde : stratégies pour les biothérapies - Revue Médicale Suisse
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxORE95eDl3T0JHNzQzcWxtdy1BOHRxR083cXpCeUdza0NfTm1JdWVJWWpPYUk2LUpuOVNZN3pTYTZaT2djNjdWcmNVTnk1R1F0QmFkTlZvQUxYeE5uVnZuenpCY3lQbmgxdmVaSjduTEI3TFBWX1hhbkQ4QUhkWVk3NWQzRUZxV2NNVlcyM29MWFhrOG1wQ0g5WmV2YjAwUWM3U2xrVHBmUlZod09Vc2xiX2dpLTNGdU9VQT
Direction de thèses
2Encadrement de doctorants — signal d'activité universitaire.
Données issues de l'Annuaire Santé (ANS) — Licence Ouverte 2.0. Enrichissements à partir de sources publiques. Vous êtes le praticien référencé ? Faites corriger ou retirer votre fiche : demande de rectification ou de retrait.